Phase II trial of nab-paclitaxel in patients with relapsed or refractory multiple myeloma

Tania Jain; Amylou C. Dueck; Heidi e. Kosiorek; Brenda F. Ginos; Angela Mayo; Craig B. Reeder; Marta Chesi; Joseph Mikhael; A. Keith Stewart; P. Leif Bergsagel; Rafael Fonseca

doi:10.1002/ajh.24548

Phase II trial of nab-paclitaxel in patients with relapsed or refractory multiple myeloma

Tania Jain, Amylou C. Dueck, Heidi e. Kosiorek, Brenda F. Ginos, Angela Mayo, Craig B. Reeder, Marta Chesi, Joseph Mikhael, A. Keith Stewart, P. Leif Bergsagel, Rafael Fonseca

Research output: Contribution to journal › Letter › peer-review

5 Scopus citations

Original language	English (US)
Pages (from-to)	E504-E505
Journal	American journal of hematology
Volume	91
Issue number	12
DOIs	https://doi.org/10.1002/ajh.24548
State	Published - Dec 1 2016

ASJC Scopus subject areas

Hematology

Access to Document

10.1002/ajh.24548

Cite this

@article{1b1e3c74b3d04293bfe4c7e7725ea7bd,

title = "Phase II trial of nab-paclitaxel in patients with relapsed or refractory multiple myeloma",

author = "Tania Jain and Dueck, {Amylou C.} and Kosiorek, {Heidi e.} and Ginos, {Brenda F.} and Angela Mayo and Reeder, {Craig B.} and Marta Chesi and Joseph Mikhael and {Keith Stewart}, A. and {Leif Bergsagel}, P. and Rafael Fonseca",

note = "Funding Information: Conflict of interest: CBR – Research funding from Celgene; JM – Institutional research funding from Abbvie, Celgene, Onyx, Sanofi; AKS – Celgene; PLB – Amgen, BMS, Novartis, Incyte (consultant) and Novartis (research); RF – Celgene.",

year = "2016",

month = dec,

day = "1",

doi = "10.1002/ajh.24548",

language = "English (US)",

volume = "91",

pages = "E504--E505",

journal = "American journal of hematology",

issn = "0361-8609",

publisher = "Wiley-Liss Inc.",

number = "12",

}

TY - JOUR

T1 - Phase II trial of nab-paclitaxel in patients with relapsed or refractory multiple myeloma

AU - Jain, Tania

AU - Dueck, Amylou C.

AU - Kosiorek, Heidi e.

AU - Ginos, Brenda F.

AU - Mayo, Angela

AU - Reeder, Craig B.

AU - Chesi, Marta

AU - Mikhael, Joseph

AU - Keith Stewart, A.

AU - Leif Bergsagel, P.

AU - Fonseca, Rafael

N1 - Funding Information: Conflict of interest: CBR – Research funding from Celgene; JM – Institutional research funding from Abbvie, Celgene, Onyx, Sanofi; AKS – Celgene; PLB – Amgen, BMS, Novartis, Incyte (consultant) and Novartis (research); RF – Celgene.

PY - 2016/12/1

Y1 - 2016/12/1

UR - http://www.scopus.com/inward/record.url?scp=84995579548&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995579548&partnerID=8YFLogxK

U2 - 10.1002/ajh.24548

DO - 10.1002/ajh.24548

M3 - Letter

C2 - 27581088

AN - SCOPUS:84995579548

SN - 0361-8609

VL - 91

SP - E504-E505

JO - American journal of hematology

JF - American journal of hematology

IS - 12

ER -

Phase II trial of nab-paclitaxel in patients with relapsed or refractory multiple myeloma

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this